ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for response stratification still need further screening. In the present study, a total of 399 patients with high-quality ctDNA profil...

Full description

Bibliographic Details
Main Authors: Jun Lu, Yanwei Zhang, Yuqing Lou, Bo Yan, Benkun Zou, Minjuan Hu, Yanan Wang, Ya Chen, Zhengyu Yang, Huimin Wang, Wei Zhang, Baohui Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Genetics
Subjects:
UBL
biomarker
immune checkpoint inhibitors
atezolizumab
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.723670/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.723670/full

Similar Items